Tuojie Life, Worun Hope To accurately write the miracle of life, Tuoshuwo ® (Aivnibu Film) China Listing Conference · East China Railway Station was successfully held!

Fanglin new leaves promote Chen leaves, and thousands of sails compete to make Vientiane new

Opening remarks at the conference

Opening speech and meeting site

Professor Wu Depei said in his speech that the listing of Avonib fills the gap of IDH1 mutation AML targeted therapy in China and is of landmark significance

Professor Li Junmin said that Aivonib has achieved from application to approval in a short period of time, which is expected to open a new era of

Professor Ji Chunyan believes that doctors attach great importance to the clinical application of specific target drugs, and the listing of Avnib will further enhance the level

Dr.

After the wonderful opening speech, many experts joined hands to launch the ceremony and jointly lit up the light

Avonib China Listing Conference · Launching ceremony of East China Railway Station

Leading the Precise: The present and future of AML precision care

Professor Zhang Sujiang made a wonderful report

Under the co-chairmanship of Professor Li Junmin and Professor Liang Aibin of Tongji Hospital affiliated to Tongji University, Professor Zhang Sujiang of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine shared the following thoughts on the present and future of AML precision diagnosis and treatment:

➤With the development of diagnosis and treatment technology, under the framework of stratified treatment guided by cytogenetics, molecular genetics and minimal residual disease (MRD), the survival rate of AML patients, especially young AML patients, has gradually improved, but the survival rate of elderly AML patients still needs to be improved
.

➤ Precision targeted therapy drugs represented by evonib provide AML patients with a "double-excellent" treatment option that takes into account both efficacy and safety, and monotherapy for IDH1 mutant R/R AML patients reaches the median OS of CR/CRh patients for 18.
8 months, and the incidence of adverse events related to ≥ level 3 treatment is low, and it also provides an opportunity
for clinical exploration of different mechanisms of drug combination schemes.

➤ In the future, AML treatment will move towards the era of precision treatment, and the construction of AML precision diagnosis and treatment mode based on accurate detection, accurate diagnosis, precision treatment, and accurate monitoring will become an important trend
in future development.

Celebrity dialogue

Professor Li Zhenyu of the Affiliated Hospital of Xuzhou Medical University, Professor Wang Wei of the Affiliated Hospital of Qingdao University and Professor Wang Xiaoqin of Huashan Hospital Affiliated to Fudan University had a heated discussion on the above topics, saying that the emergence of genetic testing technology and a variety of targeted drugs has brought tangible changes to AML diagnosis and treatment, and diversified combination drug programs should be actively explored in the future to bring greater benefits
to patients.

Tron Innovation: The Path to Exploration of the IDH1 Mutation AML

Professor Chen Suning made a wonderful report

Under the co-chairmanship of Professor Hou Ming of Qilu Hospital of Shandong University and Professor Chang Chunkang of Shanghai Sixth People's Hospital, Professor Chen Suning of the First Affiliated Hospital of Soochow University elaborated on the exploration of IDH1 mutation AML, the main points are as follows:

➤ Targeted tumor metabolism mutation is a hot topic of exploration, IDH1 is one of the most representative mutation metabolic genes, IDH1 inhibitor Avonib is a representative targeted drug to achieve the first breakthrough, which can quickly inhibit the production of 2-HG and reduce it to normal physiological level, inducing normal differentiation
.

➤ Avnib and chemotherapy, demethylation therapy, apoptosis inducers and other mechanism drugs have shown synergy and achieved good efficacy
.
Authoritative guidelines at home and abroad have recommended evonib monotherapy or combined demethylation drugs for the treatment of patients with IDH1 mutation initial treatment
or recurrent refractory AML.

➤ Avnib also has room to play in areas such as post-transplant maintenance therapy, and looks forward to breakthroughs
in the future.

Celebrity dialogue

Professor Chen Chunyan of Qilu Hospital of Shandong University, Professor Chu Xiaoxia of Yantai Yuhuangding Hospital and Professor Xu Hongzhi of Shandong Provincial Hospital shared their thoughts on the exploration of IDH1 mutation AML, believing that the safety of Aivonibu is more prominent than other targeted drugs, the degree of adverse reactions is relatively light, the future application space is relatively broad, and clinical practice can try to explore new models such as combination drugs to further accumulate clinical experience
.

Dingxin Light: New ideas for AML diagnosis and treatment from the update of the guide

Professor Shen Yang made a wonderful report

Under the co-chairmanship of Professor Chen Bing of Nanjing Drum Tower Hospital and Professor Song Xianmin of the First People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Shen Yang of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine shared new ideas for AML diagnosis and treatment based on the update of domestic and foreign guidelines, the main contents of which are as follows:

➤ Molecular genetics-guided AML prognostic stratification in authoritative guidelines at home and abroad has been gradually refined, and MRD has also been valued for treatment evaluation
.
Since 2019, NCCN guidelines have recommended AML precision treatment regimens based on whether there are mutant targets, and IDH1 mutations are one of the
representative targets.

➤ The CR+CRh rate of patients with relapsed refractory AML in the treatment of IDH1 mutation reached 36.
7%, and 90.
9% of patients could maintain continuous remission of CR+CRh for 12 months, and the patient's hematological indicators were significantly improved
.

➤ Precision treatment under the guidance of molecular detection is the future development direction of AML treatment, and attention should be paid to exploring maintenance treatment strategies
for AML patients.

Celebrity dialogue

Professor Bi Kehong of Qianfoshan Hospital of Shandong Province, Professor Gu Weiying of Changzhou First People's Hospital and Professor Xue Shengli of the First Affiliated Hospital of Soochow University had a heated discussion on the above contents, believing that Evonibu's bone marrow inhibition degree is relatively mild, and in practice, patients generally do not do dose reduction treatment under tolerable conditions, but they should pay attention to avoiding drug interactions as much as possible, and the specific conclusions need to be confirmed by
more clinical and real-world studies.

The Light of Protection: Interpretation and Reflection of Important Clinical Research Data of Tuoshuwo ^®

Professor Qiu Huiying made a wonderful report

Under the co-chairmanship of Professor Hao Siguo of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Professor Tang Xiaowen of the First Affiliated Hospital of Soochow University, Professor Qiu Huiying of the First Affiliated Hospital of Soochow University deeply interpreted the important clinical research data on Avnib and shared the following thoughts:

➤ In terms of monotherapy, the CR/CRh rate of R/R AML patients with IDH1 mutation reached 36.
7%, and the median overall survival (OS) of CR/CRh patients reached 18.
8 months; the CR/CRh rate of newly diagnosed IDH1 mutation AML patients who did not meet the standard of care (SOC) was 42.
4%, and the median OS rate was 12.
6 months
.
And all avoid severe bone marrow suppression, and the incidence of adverse reactions is low
.

➤ In terms of combination drugs, the median OS of newly diagnosed IDH1 mutation AML patients with intolerable strongly induced chemotherapy was 24 months in the treatment of avonib plus azacitine therapy, and the overall 1-year OS rate of newly diagnosed IDH1 mutation AML patients who could tolerate strong induced chemotherapy with combined chemotherapy regimen was 80%.

➤ The exploration of the diversified applications of Evnib in tumors is also underway, such as the treatment of AML with other small molecule targeted drugs, maintenance therapy after IDH1 mutation AML transplantation, treatment of other myeloid hematologic tumors, and solid tumor applications
.

Celebrity dialogue

Professor Ding Yi of Tongji Hospital Affiliated to Tongji University, Professor Qian Sixuan of Jiangsu Provincial People's Hospital and Professor Tong Yin of Shanghai First People's Hospital had a heated discussion
on the core research of Aifenib.
At present, there are many clinical exploration of two drugs and even multi-drug combination treatment modes, some of which have made gratifying progress, but in the process of practice, attention should be paid to the standardization of medication and strengthen the monitoring and management
of patients.

Tuoshuwo ^® R&D road and cornerstone R&D pipeline

Dr.
Tieqin Liu, Business Assistant to the CEO of Cornerstone Pharmaceuticals and Head of Clinical Strategy and Planning, briefly shared the research and development path of Avnib and the innovative R&D pipeline of Cornerstone Pharmaceuticals, saying that Cornerstone Pharmaceuticals adheres to the spirit of exploration, attaches importance to the development of immunology and targeted two-wheel drive products, and will further explore the application of Avnib in other tumors, including solid tumors, at present, the FDA has approved Avnib for the treatment of IDH1 mutant cholangiocarcinoma, in addition to a number of clinical studies covering different tumor fields are underway.
We'll see
.

Dr.
Liu Tieqin made a wonderful report

Mechanics: Introduction to Evnib in the Treatment of IDH1 Mutation AML Cases

Professor Liu Ligen made a wonderful report

Under the co-chairmanship of Professor Zhao Hongguo of the Affiliated Hospital of Qingdao University and Professor Miao Wei of the First Affiliated Hospital of Soochow University, Professor Liu Ligen of Tongren Hospital Affiliated to Shanghai Jiao Tong University School of Medicine shared the diagnosis and treatment process and thoughts of a case of IDH1 mutation AML patient:

➤ The elderly female patient was diagnosed with AML-M4 at the first visit, and reached CR after giving chemotherapy, but then the disease recurred, and a variety of chemotherapy regimens were given, and there were still tumor cells left
.
Genetic testing found that IDH1 mutation rate (44.
9%), given evonib treatment, the patient's blood picture is stable, granulocyte count recovery is obvious, and the condition is stable after discharge
.
Since the follow-up has been followed up with evonib maintenance therapy, he is still in CR status and has a good
quality of life.

➤The cause of the above changes in the patient's granulocytes may be related
to the mechanism of evonib induced differentiation.

➤ Patients with sustained CR and survival time of more than 6 years have achieved clinical cure, which may be closely related
to the fact that Ivonib can be targeted on leukemia stem cells as a precision targeted therapy drug.

Celebrity dialogue

Professor Han Xiaofeng of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Professor Sun Xuemei of Nanjing University of Chinese Medicine shared their feelings about the above-mentioned AML cured cases and had a heated discussion
with Professor Liu Ligen.
The process of case diagnosis and treatment shows that Evnib can significantly benefit patients with IDH1 mutation AML, so that patients can transition from CRi to CR and sustainable CR status, and the specific mechanism needs to be further explored
.

Summary of the meeting

At the end of the meeting, Professor Li Junmin said that Avonib significantly improved the median OS and long-term survival rate of AML patients, which is of great significance, the overall treatment field of AML has made rapid progress, and in the future, I hope that the workers in the field of hematology and related institutions will cooperate sincerely to benefit more patients; Professor Ji Chunyan believes that this conference systematically analyzes the diagnosis and treatment of IDH1 mutation AML from multiple perspectives, thanks to the active participation of experts and the full support of CStone Pharmaceuticals, and looks forward to working together in the future to bring more benefits
to AML patients.